Toyota|$18.23 (¥2,915)+2.48%▲ (in JPY terms)
Sony|$22.79 (¥3,645)-0.65%▼ (in JPY terms)
SoftBank|$52.09 (¥8,329)-3.51%▼ (in JPY terms)
MUFG|$19.57 (¥3,129)+2.72%▲ (in JPY terms)
Keyence|$505.73 (¥80,870)+3.23%▲ (in JPY terms)
Nintendo|$46.63 (¥7,457)+0.42%▲ (in JPY terms)
NTT|$0.92 (¥148)+0.00%▲ (in JPY terms)
Takeda|$29.64 (¥4,740)-2.27%▼ (in JPY terms)
Tokyo Electron|$380.65 (¥60,870)+13.33%▲ (in JPY terms)
Recruit|$67.76 (¥10,835)-0.09%▼ (in JPY terms)
ITOCHU|$11.62 (¥1,858)+0.03%▲ (in JPY terms)
Honda|$9.36 (¥1,498)+7.97%▲ (in JPY terms)
Shin-Etsu|$48.62 (¥7,774)+4.03%▲ (in JPY terms)
Tokio Marine|$44.43 (¥7,105)+0.84%▲ (in JPY terms)
Fast Retailing|$494.97 (¥79,150)-0.67%▼ (in JPY terms)
Toyota|$18.23 (¥2,915)+2.48%▲ (in JPY terms)
Sony|$22.79 (¥3,645)-0.65%▼ (in JPY terms)
SoftBank|$52.09 (¥8,329)-3.51%▼ (in JPY terms)
MUFG|$19.57 (¥3,129)+2.72%▲ (in JPY terms)
Keyence|$505.73 (¥80,870)+3.23%▲ (in JPY terms)
Nintendo|$46.63 (¥7,457)+0.42%▲ (in JPY terms)
NTT|$0.92 (¥148)+0.00%▲ (in JPY terms)
Takeda|$29.64 (¥4,740)-2.27%▼ (in JPY terms)
Tokyo Electron|$380.65 (¥60,870)+13.33%▲ (in JPY terms)
Recruit|$67.76 (¥10,835)-0.09%▼ (in JPY terms)
ITOCHU|$11.62 (¥1,858)+0.03%▲ (in JPY terms)
Honda|$9.36 (¥1,498)+7.97%▲ (in JPY terms)
Shin-Etsu|$48.62 (¥7,774)+4.03%▲ (in JPY terms)
Tokio Marine|$44.43 (¥7,105)+0.84%▲ (in JPY terms)
Fast Retailing|$494.97 (¥79,150)-0.67%▼ (in JPY terms)

JP3188220002

2026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (ADHD) treatment with a new mechanism of action, was presented at the American Society of Clinical Psychopharmacology (ASCP) annual meeting with post-hoc analysis results from a Phase 3 trial demonstrating improvements in executive function and emotional regulation in adults with ADHD.”

by

2026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (AD … 続きを読む

2026-05-14 Otsuka Holdings Co.,Ltd. “The US FDA has approved INQOVI and venetoclax combination therapy as the first oral-only combination therapy for patients with acute myeloid leukemia who are not suitable for intensive induction therapy.”

by

2026-05-14 Otsuka Holdings Co.,Ltd. “The US FDA has approved INQOVI and venetoclax combination therapy a … 続きを読む

2026-04-30 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical has released a collection of educational materials and resources for teachers and staff to support health education in schools. Electronic health materials on topics such as heatstroke prevention and nutrition education are available free of charge.”

by

2026-04-30 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical has released a collection of educational mate … 続きを読む

2026-04-28 Otsuka Holdings Co.,Ltd. “Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics have had their New Drug Application (NDA) for diparereltinib for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations accepted by the U.S. FDA.”

by

2026-04-28 Otsuka Holdings Co.,Ltd. “Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics hav … 続きを読む

Contact